Evaluation of a Standardized Strategy for Uveitis Etiological Diagnosis

NCT ID: NCT01162070

Last Updated: 2025-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

905 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Uveitis, the inflammation of the uvea, is a rare disease with an incidence of 52/100,000 inhabitants per year and a prevalence of 115 / 100,000 inhabitants per year.

The causes of uveitis are numerous and include infectious diseases, systemic and neurological diseases, ophthalmic entities, neoplasia, and drug-related reactions. The etiological diagnosis is important both for prognosis and therapeutics.

However, clinical evaluations to establish etiological diagnosis are not standardized. Some authors suggest a minimalist examination, common to all kinds of uveitis. On the other hand, others propose an evaluation guided by the anatomo-clinical type of uveitis.

We conducted a retrospective study to assess the contribution of complementary examinations to etiological determination. In this study, we found that most patients benefited from a wide paraclinical evaluation compared to what is usually described in the literature. Complementary examinations were mostly systematic, without any clinical or ophthalmological elements of orientation. This study highlighted the lack of contribution of some examinations.

Using these results, and the literature analysis, we designed a diagnostic algorithm adapted to the anatomo-clinical type of uveitis.

Moreover, we found that the average cost per patient was estimated at €290.51 with the algorithm compared to €560.83 without it.

We would like to carry out a new study to estimate the efficiency as well as the medico-economic impact of the use of a standardized strategy for the etiological diagnosis of uveitis, compared with a free strategy.

Hypothesis:

* The standardized strategy for the diagnostic of uveitis is at least as efficient as the free one, and costs half as much.
* The examinations prescribed, except for those from the standardized strategy, do not contribute to etiological determination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Free strategy

Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.

Group Type ACTIVE_COMPARATOR

Free strategy

Intervention Type OTHER

Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.

Experimental strategy

Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).

Group Type EXPERIMENTAL

Standardized strategy

Intervention Type OTHER

Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Free strategy

Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.

Intervention Type OTHER

Standardized strategy

Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Procedure or strategy leading to the etiological diagnosis of the uveitis.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Uveitis
* Patient consulting one of the study's sites
* Age \> 18 years old
* Affiliation to the French national health insurance program
* Patient agreeing to participate in the study

Exclusion Criteria

* Positive HIV serology
* Postsurgical or posttraumatic uveitis or endophthalmitis
* Toxoplasmic uveitis
* Pathology likely to be the cause of the known uveitis
* Ophthalmic entities only diagnosed by the ophthalmic examination
* Age \< 18 years old
* Patient under law protection or guardianship
* Pregnant women or those planning to be pregnant during the study
* Severe uveitis (VA \< 20/200) with retinal vascularitis requiring an emergency treatment and assessment.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Médecine Interne, Hospices Civils de Lyon (HCL)-Hôpital de la Croix Rousse

Lyon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

de Parisot A, Kodjikian L, Errera MH, Sedira N, Heron E, Perard L, Cornut PL, Schneider C, Riviere S, Olle P, Pugnet G, Cathebras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Vicente S, Bin S, Broussolle C, Decullier E, Seve P; ULISSE group. Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). Am J Ophthalmol. 2017 Jun;178:176-185. doi: 10.1016/j.ajo.2017.03.029. Epub 2017 Mar 31.

Reference Type BACKGROUND
PMID: 28366648 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009.566/19

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Analysis of Eye Tissue
NCT00001224 COMPLETED
Immune Indicators of Uveitis
NCT00089739 COMPLETED
Apremilast in the Treatment of Uveitis
NCT00889421 TERMINATED PHASE1/PHASE2
Leflunomide to Treat Uveitis
NCT00001863 COMPLETED PHASE2
Treatment FOr Corticosteroid Dependent UveitiS
NCT06258915 NOT_YET_RECRUITING PHASE3